Cancers, Vol. 16, Pages 857: Perioperative Chemotherapy Including Bevacizumab in Potentially Curable Metastatic Colorectal Cancer: Long-Term Follow-Up of the ASSO-LM1 Trial

In conclusion, the ASSO-LM1 trial is a hypothesis-generating study confirming the prognostic benefits of perioperative therapy with XELOX and bevacizumab in patients with metastatic colorectal cancer confined to the liver.

Source: Cancers - February 21, 2024 Category: Cancer & Oncology Authors: Yawen Dong Jonas Santol Birgit Gruenberger Alfred Lenauer Friedrich Laengle Josef Thaler Gudrun Piringer Wolfgang Eisterer Angela Djanani Judith Stift Thomas Gruenberger Tags: Article Source Type: research